Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening-Reference-Cited by-同舟云学术

Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening

Published:2018-06 Issue:6 Volume:73 Page:961-967
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Assel Melissa,Dahlin Anders,Ulmert David,Bergh Anders,Stattin Pär,Lilja Hans,Vickers Andrew J.

Publisher

Elsevier BV

Subject

Urology

Reference12 articles.

1. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context;Draisma;J Natl Cancer Inst,2009

2. Lead-time in the European Randomised Study of Screening for Prostate Cancer;Finne;Eur J Cancer,2010

3. Lead time associated with screening for prostate cancer;Tornblom;Int J Cancer,2004

4. Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening;Savage;Cancer Epidemiol Biomarkers Prev,2010

5. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends;Etzioni;J Natl Cancer Inst,2002

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only;New England Journal of Medicine;2022-12-08

2. The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the Göteborg-1 Prostate Cancer Screening Trial;European Urology;2022-09

3. The Effect of Age on Prostate Cancer Survival;Cancers;2022-08-27

4. A randomized trial of risk‐adapted screening for prostate cancer in young men—Results of the first screening round of the PROBASE trial;International Journal of Cancer;2022-02-17

5. Risikoadaptierte Früherkennung des Prostatakarzinoms – Update 2021;Der Urologe;2021-04-01